NEW YORK, September 29, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on the following equities: AMAG Pharmaceuticals, Inc.  (NASDAQ: AMAG), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Amarin Corporation PLC (NASDAQ: AMRN), Epizyme, Inc. (NASDAQ: EPZM), EXACT Sciences Corporation (NASDAQ: EXAS). On Monday, September 28, 2015, Nasdaq ended at 4543.97, down 3.04%, Dow Jones declined 1.92%, to finish the day at 16001.89, and the S&P closed at 1881.77, down 2.57%. Register for your complimentary reports at the links given below.  

--

AMAG Pharmaceuticals Inc 

--

AMAG Pharmaceuticals Inc's stock edged lower by 8.85% to close Monday's session at USD 39.86. The company's shares oscillated between USD 38.51 and USD 44.48. The stock recorded a trading volume of 2.06 million shares, which was above its 50-day daily average volume of 1.12 million shares and above its 52-week average volume of 0.80 million shares. Over the last three days, AMAG Pharmaceuticals Inc's shares have declined by 12.63% and in the past one week it has moved down 13.25%. Furthermore, over the last three months, the stock has lost 40.63% and in the past six months, the shares have shed 29.05%. Further, the company is trading at a price to earnings ratio of 6.71 and a price to book ratio of 1.73. This compares to a historical PE ratio of 7.92. The historical PB ratio is near to 2.37. Additionally, the stock is trading at a price to cash flow ratio of 10.87 and price to sales ratio of 4.64. Sign up and read the free notes on AMAG at:

http://www.aciassociation.com/AMAG.pdf

--

Halozyme Therapeutics Inc 

--

The stock of Halozyme Therapeutics Inc lost 9.49% to close Monday's session at USD 14.50. The shares of the company moved in the range of USD 14.25 and USD 15.90. A trading volume of 1.97 million shares was recorded, which was greater than its 150-day daily average volume of 1.41 million shares and above its 52-week average volume of 1.49 million shares. Over the last five days, Halozyme Therapeutics Inc's shares have declined by 20.42% and in the past one month, it has lost 16.95%. However, the stock has returned 21.24% in the past one month, and 31.41% in the last three months, on a compounded total return basis. The stock is at a price to book ratio of 36.88. The historical PB ratio is near to 29.34. Further, the stock is trading at a price to sales ratio of 17.31. Register for free on ACI Association and access the latest research on HALO at:

http://www.aciassociation.com/HALO.pdf

--

AMARIN CORPORATION PLC 

--

AMARIN CORPORATION PLC's stock decreased by 7.27% to close Monday's session at USD 2.04. The company's shares fluctuated in the range of USD 1.99 and USD 2.16. A total of 1.97 million shares exchanged hands, which surpassed its 50-day daily average volume of 1.67 million shares and was below its 52-week average volume of 2.66 million shares. Over the last three days AMARIN CORPORATION PLC's shares have declined by 10.92% and in the past one week it has moved down 12.82%. Furthermore, over the last three months, the stock has lost 11.69% and in the past six months, the shares have shed 14.64%. The complete research on AMRN is available for free at:

http://www.aciassociation.com/AMRN.pdf

--

Epizyme Inc 

--

Epizyme Inc's stock slipped by 27.22% to close Monday's session at USD 13.02. The company's shares oscillated between USD 12.00 and USD 17.99 marking a new 52-week low during the session. The stock recorded a trading volume of 1.97 million shares, which was above its 50-day daily average volume of 0.45 million shares and above its 52-week average volume of 0.41 million shares. Over the last five days, Epizyme Inc's shares have declined by 31.97% and in the past one month, it has lost 25.68%. In addition, over the last three months, the stock has lost 36.39% and year to date, the shares have shed 31.00%. Free in-depth research on EPZM is available at:

http://www.aciassociation.com/EPZM.pdf  

--

Exact Sciences Corp 

--

Exact Sciences Corp's stock declined 3.60% to close Monday's session at USD 18.22. The share price vacillated between USD 18.02 and USD 19.41. The stock recorded a trading volume of 1.97 million shares, which was above its 50-day daily average volume of 1.41 million shares and above its 52-week average volume of 1.65 million shares. Over the last three days Exact Sciences Corp's shares have declined by 5.05% and in the past one week it has moved down 1.67%. Moreover, in the last six months, the stock has lost 20.89% and year to date, the shares have shed 33.60%. The stock is at a price to book ratio of 7.22. The historical PB ratio is near to 8.42. Additionally, the stock is trading at a price to sales ratio of 126.05. The complimentary notes on EXAS can be downloaded in PDF format at:  http://www.aciassociation.com/EXAS.pdf  

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA(R) charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.  The information in this release has been sourced from a third party data base.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com